Author: Dr Anika Schröter
The development of RNA-based drugs has increased within the past years and is a promising field of research in the pharmaceutical industry. It is transforming the industry and will offer new hope for patients with unmet medical needs.
RNA-based drugs have several advantages over conventional drugs, such as the ability to target previously undruggable pathways, the rapid and cost-effective development, and the potential for personalized medicine. However, RNA-based drugs also face some challenges, such as the stability, delivery, and safety of the RNA molecules.
This whitepaper informs about the challenges with the 'standard' non-clinical program for different RNA-based drugs, focusing on safety evaluation.
Download now the white paper 'Non-clinical aspects of RNA-based drug development'.
We hope you enjoy reading it!
The conference will cover recent updates and practical implications of the EU pharmaceutical legislation, the application of AI in RA, and the new EU Variation regulation. Additionally, it will address the latest developments in quality (draft) guidelines: ICH M13a and M13B, ICH M4Q(R2), EU GMP Annex 11, New Annex 22 on AI, and an update on the ongoing discussions on nitrosamine "contaminations".
Gain strategic insights into utilizing prior use rights across multiple jurisdictions in this practical course. Learn to assert defense rights effectively before the UPC, EPO, and national courts in Germany, China, and the US, through the analysis of diverse case studies.
Gain a thorough understanding of the latest accounting standards for national and international banks through detailed examples, all available online.
We will focus on how to integrate compliance and governance into Medical Affairs activities and ensure quality documentation that is both effective and pragmatic.
This course offers a deep dive into patient involvement in HTA processes across Europe, with a focus on the UK and Germany - learn practical approaches, regulatory insights, and how to engage meaningfully with patient organisations.
This online webcast series provides a concise update on the EU Pharmaceutical Package. Across five two-hour modules, you learn about key regulatory changes, revised authorisation and protection rules, new obligations for managing shortages, and developments in environmental risk assessment. Gain practical guidance to adapt internal processes and responsibilities to the upcoming framework.
The seminar covers essential topics such as stakeholder identification, effective meeting preparation, and legally compliant collaboration. Tailored for Medical Science Liaisons (MSLs) and Medical Affairs teams, the seminar equips you to gain real insights from KOLs, overcome challenging situations, and elevate patient outcomes.
Stay informed with updates from our global and local experts, who will provide the latest regulatory and legislative insights every two months. In 2026, topics will include CMC documentation, regulatory intelligence, regulatory pathways in Africa, enrichment of PMS product data, global regulatory reliance models and ePI.
MedTech experts will provide you with updates every two months on the latest regulatory and legislative developments. This way, you will always have the key information and current trends in regulatory affairs at your fingertips.
